Use of concurrent sedating agents provides rapid sedation and reduces the need for resedation in acutely agitated patients, according to clinical trial results published online in the Annals of Emergency Medicine.
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More